Lorigerlimab
Multispecific antibody
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
Development in Metastatic Castration-Resistant Prostate Cancer stopped (2025-11-12) after a negative readout. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05848011 NCT05848011 · Metastatic Castration-Resistant Prostate Cancer Registry: NCT05848011 | 2 | Median radiographic progression free survival (rPFS) determined by investigator review. (Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years) 2026-02-19 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other PD-1 x CTLA-4 drugs
Iparomlimab and tuvonralimab, Volrustomig, Danvilostomig, AI-061. Compare all 5 PD-1 x CTLA-4 drugs
4 other tracked programmes target this mechanism, 2 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lorigerlimab: this drug | Phase 2 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary | |
| Iparomlimab And Tuvonralimab | Phase 3(overall) | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary | |
| Volrustomig | Phase 3(overall) | Multispecific antibody | PD-1 x CTLA-4 | Partial signal | NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed | |
| Danvilostomig | Phase 2(overall) | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary | |
| AI-061 | Phase 1(overall) | Combination | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lorigerlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.